Daiichi Sankyo expands its OTC reach; Mylan to prohibit sales of drug for executions;

@FiercePharma: MSF campaigns at UN summit meeting to ease pressure on India's drug IP policies. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: Obstacles aside, Boehringer sees class-topping prospects for Ofev, Spiolto. FiercePharmaMarketing story | Follow @CarlyHFierce

> Daiichi Sankyo has acquired ImCo, a growing mail-order OTC drug and cosmetics maker. Report

> Mylan ($MYL), bending to pressure, has agreed like many other drugmakers to write contracts that prevent distributors from selling its drug rocuronium bromide for use in lethal injections. Story

> The maker of the first liquid dose aspirin is looking for a partner. Report

> French vaccine maker Abivax is conducting clinical trials on a hepatitis C vaccined developed in Cuba. Story

Medical Device News

@FierceMedDev: Illumina expands in China with cancer Dx deal. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Study: Oraya radiation tech reduces need for eye injections in AMD patients. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: U.K. patient group demands government override Roche's Kadcyla patents. Article | Follow @EmilyWFierce

> Google sees independent startups as key to new Alphabet reorganization. Report

> NIH's BRAIN initiative, philanthropic Kavli Foundation provide $185M to study brain science. More

> Siemens nabs Abbott SVP to run healthcare in North America. Article

Biotech News

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

@DamianFierce: Today's the FDA decision deadline for Keytruda's lung cancer app. Can't wait to see the TV ad. | Follow @DamianFierce

> XenoPort hits reset after a psoriasis setback, cutting jobs and bailing on R&D. Report

> Regeneron inks a $325M deal, selling Asian rights to a pain treatment. Story

> Sanofi steps deeper into RNAi work, opts in on Alnylam hemophilia drug. Article

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.